Multicenter Analysis of Neoadjuvant Docetaxel, Carboplatin, and Trastuzumab (TCH) in Patients With HER2-Positive Breast Cancer

This retrospective analysis reviewed all the incident stage I-III HER2-positive breast cancer patients who received neoadjuvant TCH in three institutions. Overall, TCH was well tolerated, with low rates of grade 3-4 adverse events, and neither late toxicities nor cardiac dysfunctions were reported.

 Breast Cancer Res Treat